290650 — L&C Bio Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩445bn
- KR₩477bn
- KR₩69bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 29,152 | 32,973 | 45,677 | 52,572 | 68,870 |
Cost of Revenue | |||||
Gross Profit | 18,664 | 19,558 | 28,450 | 26,992 | 34,770 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 20,119 | 25,649 | 32,503 | 43,048 | 63,497 |
Operating Profit | 9,032 | 7,324 | 13,174 | 9,524 | 5,372 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 9,922 | 12,944 | 17,095 | 4,563 | 62,938 |
Provision for Income Taxes | |||||
Net Income After Taxes | 8,454 | 12,149 | 15,580 | 5,692 | 48,531 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 7,250 | 10,813 | 13,814 | 4,544 | 48,361 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 7,250 | 10,813 | 13,814 | 4,544 | 48,361 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 330 | 494 | 618 | 197 | 2,207 |
Dividends per Share |